IND Acceptance

Nxera Pharma Earns $10M Milestone as Neurocrine Wins FDA Acceptance for Alzheimer’s Phase 2 Study

Tokyo, Japan and Cambridge, UK — August 26, 2026 Nxera Pharma Co., Ltd. announced that its partner Neurocrine Biosciences...

By cGxPwire Editor
August 28, 2026

Bio-Pharma

Humacyte FDA Accepts IND for First-in-Human CTEV CABG Study

DURHAM, N.C., July 27, 2026 Humacyte, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted its...

By cGxPwire Editor
July 28, 2026

.Clinical

Harbour BioMed Clears Regulatory Milestone for HBM7004

CAMBRIDGE, Massachusetts; ROTTERDAM, Netherlands; SHANGHAI, China, June 10, 2026 Harbour BioMed announced that the National Medical Products Administration (NMPA)...

By cGxPwire Editor
June 10, 2026

We work Hard to get you posted with latest updates

Unwrap our new Directory

Nxera Pharma Earns $10M Milestone as Neurocrine Wins FDA Acceptance for Alzheimer’s Phase 2 Study

Humacyte FDA Accepts IND for First-in-Human CTEV CABG Study

Harbour BioMed Clears Regulatory Milestone for HBM7004